Lantern Pharma Newsroom

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA For Treatment Of Triple Negative Breast Cancer

BenzingaDec 3 08:12 ET

Express News | Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA for Treatment of Triple Negative Breast Cancer (Tnbc)

ReutersDec 3 08:00 ET

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

BusinesswireNov 26 08:45 ET

Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

ReutersNov 26 08:45 ET

Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

ReutersNov 19 08:00 ET

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 8 19:23 ET

Lantern Pharma Advances AI-Driven Cancer Therapies

TipRanksNov 7 23:48 ET

Lantern Pharma Reports Q3 EPS (42c), One Estimate (56c)

TipRanksNov 7 16:26 ET

Lantern Pharma | 10-Q: Q3 2024 Earnings Report

SECNov 7 16:14 ET · Announcements

Lantern Pharma | 8-K: Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

SECNov 7 16:08 ET

Express News | Lantern Pharma Q3 Net Income USD -4.5 Million

ReutersNov 7 16:05 ET

Express News | Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

ReutersNov 5 08:00 ET

Earnings Preview: LTRN to Report Financial Results Post-market on November 07

Moomoo NewsNov 1 08:45 ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

BusinesswireOct 23 08:45 ET

Lantern Pharma to Host & Participate in Two Public Webinars During October

Yahoo FinanceOct 21 08:00 ET

Express News | Lantern Pharma Inc - Phase 1B/2a Trial for Recurrent GBM to Start Late 2024

ReutersOct 15 09:07 ET

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA

BusinesswireOct 15 09:07 ET

Express News | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA

ReutersOct 15 09:07 ET

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Yahoo FinanceOct 9 17:56 ET

Lantern Appoints Piers Dixon as Head of Sales

BusinesswireOct 7 11:23 ET